---
title: "Inogen Q1 revenue rises on international demand"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/285616797.md"
datetime: "2026-05-07T20:47:53.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/285616797.md)
  - [en](https://longbridge.com/en/news/285616797.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/285616797.md)
---

# Inogen Q1 revenue rises on international demand

)

Overview

-   US respiratory device maker’s Q1 revenue grew 3.4% yr/yr, driven by international demand
-   Company authorized $30 mln share repurchase program
-   Inogen reiterated full-year 2026 revenue guidance

Outlook

-   Inogen expects Q2 2026 revenue between $94 mln and $97 mln
-   Company reiterates full-year 2026 revenue outlook of $366 mln to $373 mln
-   Inogen remains committed to driving positive adjusted EBITDA improvement in 2026

Result Drivers

-   INTERNATIONAL SALES - Higher demand for portable oxygen concentrators in international markets and favorable foreign exchange rates offset lower U.S. sales and rentals
-   COST IMPROVEMENTS - Adjusted gross margin rose due to cost improvements in total cost of revenue
-   R&D INVESTMENT - Increased research and development spending contributed to a negative adjusted EBITDA Company press release:

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q1 Beat $85.10 $82.35

Revenue mln mln (2

Analysts

)

Q1 Beat -$4 mln -$7.70

Adjusted mln (2

Net Analysts

Income )

Q1 Net -$8.30

Income mln

Q1 Miss -$1.40 -$1.35

Adjusted mln mln (2

EBITDA Analysts

)

Q1 Gross 44.50%

Margin

Analyst Coverage

-   The current average analyst rating on the shares is “buy” and the breakdown of recommendations is 3 “strong buy” or “buy”, no “hold” and no “sell” or “strong sell”
-   The average consensus recommendation for the medical equipment, supplies & distribution peer group is “buy”
-   Wall Street’s median 12-month price target for Inogen Inc is $12.00, about 68.8% above its May 6 closing price of $7.11 For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact . (This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

### Related Stocks

- [INGN.US](https://longbridge.com/en/quote/INGN.US.md)
- [XHE.US](https://longbridge.com/en/quote/XHE.US.md)
- [IHI.US](https://longbridge.com/en/quote/IHI.US.md)
- [IHF.US](https://longbridge.com/en/quote/IHF.US.md)

## Related News & Research

- [RxSight Q1 revenue beats estimates](https://longbridge.com/en/news/285437779.md)
- [Enovis Q1 sales rise 5%, beat expectations](https://longbridge.com/en/news/285526206.md)
- [This Analyst Just Upgraded Fluence Energy Stock. Here's Why.](https://longbridge.com/en/news/285764557.md)
- [Israel's InMode Q1 adjusted profit misses, hurt by higher costs](https://longbridge.com/en/news/285364816.md)
- [Mettler-Toledo Q1 sales slightly beat estimates](https://longbridge.com/en/news/285615016.md)